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Acute colitis causes alterations in the intestinal microbiota, but the microbiota is thought
to recover after such events. Extreme microbiota alterations are characteristic of human
chronic inflammatory bowel diseases, although alterations reported in different studies
are divergent and sometimes even contradictory. To better understand the impact
of periodic disturbances on the intestinal microbiota and its compositional difference
between acute and relapsing colitis, we investigated the beginnings of recurrent
inflammation using the dextran sodium sulfate (DSS) mouse model of chemically
induced colitis. Using bacterial 16S rRNA gene-targeted pyrosequencing as well as
quantitative fluorescence in situ hybridization, we profiled the intestinal and stool
microbiota of mice over the course of three rounds of DSS-induced colitis and recovery.
We found that characteristic inflammation-associated microbiota could be detected in
recovery-phase mice. Successive inflammation episodes further drove the microbiota
into an increasingly altered composition post-inflammation, and signatures of colitis
history were detectable in the microbiota more sensitively than by pathology analysis.
Bacterial indicators of murine colitis history were identified in intestinal and stool
samples, with a high degree of consistency between both sample types. Stool may
therefore be a promising non-invasive source of bacterial biomarkers that are highly
sensitive to inflammation state and history.
Keywords: DSS, colitis, IBD, FISH, Mucispirillum, Akkermansia, Bacteroides
INTRODUCTION
The intestinal microbiota is increasingly acknowledged to play an important role in health
and disease (Clemente et al., 2012; Flint et al., 2012; Tremaroli and Backhed, 2012; Cotillard
et al., 2013). Long-term studies have demonstrated that the adult human and mouse microbiota
retains a relatively similar composition over months and even years (Caporaso et al., 2011;
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Schloss et al., 2012; Faith et al., 2013; David et al., 2014a).
However, microbial communities in all ecosystems are subject
to disturbances; changes in conditions that directly or indirectly
alter the community (Shade et al., 2012). The intestinal
microbiota is no exception. For example, shifts in diet can
produce rapid and pronounced alterations in the microbiota
(David et al., 2014a,b). In addition to diet, stressors such as
antibiotic treatment, enteric infection, and colitis can induce
remodeling of the gut microbiota (Garrett et al., 2007; Stecher
et al., 2010; Dethlefsen and Relman, 2011; Lepage et al., 2011).
The insensitivity of a community to disturbance is referred
to as its stability. Stability can be measured both in terms of
resistance, the degree to which a community is unresponsive to
a change in conditions, as well as the resilience, the tendency for
a community to return to its original state following a disturbance
(Shade et al., 2012). For example, long-term dietary patterns
promote a gut microbiota structure that is largely resistant to
short term dietary changes (Wu et al., 2011). Likewise, shifts
in the gut microbiota driven by dramatic changes in diet are
reversible upon reversion to the original diet (David et al.,
2014b). Therefore in the face of dietary disturbances the gut
microbiota of healthy adults can be characterized as relatively
stable, both in terms of resistance and resilience. Considering
stressors, a single treatment with antibiotics (amoxicillin or
ciproﬂoxacin) has been shown to induce major changes in the
gut microbiota (De La Cochetière et al., 2005; Dethlefsen et al.,
2008; Dethlefsen and Relman, 2011). Though the pre-antibiotic
microbiota was largely restored after treatment, some taxa were
lost and replaced by genetically similar (at the 16S rRNA gene
level) organisms. Organism replacement in antibiotic treatment
seems to partially involve functional redundancy and stochastic
shuﬄing of members of the microbiota, but functional shifts
have also been observed (Pérez-Cobas et al., 2013). Interestingly,
the microbiota response to multiple ciproﬂoxacin treatments was
distinct, suggesting that the history of antibiotic treatments has
an eﬀect on the microbiota (Dethlefsen and Relman, 2011).
Inﬂammatory bowel disease (IBD), which includes Crohn’s
disease and ulcerative colitis, are increasingly prevalent
multifactorial diseases in which the microbiota is thought to play
a role (Berry and Reinisch, 2013). IBD is characterized by chronic
and relapsing intestinal inﬂammation (Huttenhower et al.,
2014). Active inﬂammation of the human gut is associated with
dramatic changes in the microbiota, but results from published
studies of IBD are characterized by extensive inter-individual and
inter-study variability, leading to divergent or even contradictory
results among multiple studies (Berry and Reinisch, 2013;
Huttenhower et al., 2014). This is in stark contrast to animal
models of acute inﬂammation in which microbiota responses
are generally highly reproducible (Nagalingam et al., 2011; Berry
et al., 2012; Liang et al., 2014; Rauch et al., 2014; Schwab et al.,
2014; Ritchie et al., 2015). Divergent reports in IBD may be at
least partially due to diﬀerences in disease development and
inﬂammation history. To systematically address the diﬀerence
between acute and relapsing colitis on the microbiota, we
characterized the temporal stability of the intestinal microbiota
in inﬂammation-naïve mice as well as mice with a history
of repeated inﬂammation episodes using the DSS model of
chemically induced colitis. We observed that although early
recovery-phase microbiota shared reproducible similarities
across repeated colitis events, the number of previous colitis
episodes aﬀected microbiota composition. These data illustrate
that the gut microbiota is largely resilient to inﬂammation-
induced conditions, but also that colitis history leaves an imprint
on the early recovery-phase microbiota even after only a single
colitis event.
MATERIALS AND METHODS
Animal Experiments
C57BL/6 mice 6–8 weeks of age at the start of the experiment
were used. All replicates were performed simultaneously and the
animals were ordered at the same time from the same animal
facility. The experiment consisted of three 19 day cycles of
treatment and recovery, with a total of 11 mice in treatment
group and eight mice in control group. For each treatment
cycle animals were provided 2% dextran sodium sulfate (DSS,
molecular weight: 36–50 kDa, MP Biomedicals) in autoclaved
drinking water ad libitum for 5 days. Treatedmice were randomly
assigned to cages, but cage did not appreciably aﬀect microbiota
composition [permutational multivariate analysis of variance
(perMANOVA), p = 0.9]. From three to ﬁve mice were sacriﬁced
at the start of the experiment and in the recovery phase after
the conclusion of DSS treatment for full intestinal ﬂush samples.
Additionally, fecal pellets from eight mice (ﬁve DSS-treated
and three untreated controls) were collected at multiple time
points throughout the experiment. Conclusion of the recovery
phase was based on regain of body weight to the level of
control animals. Upon sacriﬁce the cecum and colon were
immediately removed and ﬂushed with 7 ml of sterile phosphate-
buﬀered saline (PBS; 136 mM NaCl, 2.6 mM KCl, 10 mM
Na2HPO4, 1.7 mM KH2PO4, pH 7.2) as described previously
(Berry et al., 2012). Pooled cecum and colon samples were used to
generate a comprehensive proﬁle of the microbiota composition
in the lower intestinal tract and has been previously validated
for DSS treatment studies (Berry et al., 2012). The intestine
was prepared as a Swiss roll, ﬁxed in 4% paraformaldehyde,
embedded in paraﬃn, and sectioned for pathology evaluation as
described previously (Stevceva et al., 1999; Williams et al., 2001;
Pﬂegerl et al., 2009). Flushed cecum and colon contents were
homogenized, collected by centrifugation and snap-frozen for
DNA puriﬁcation. All animal experiments were discussed and
approved by the institutional ethics committee and conducted
in accordance with protocols approved by the Austrian laws
(BMWF-66.006/0002-II/10b/2010).
DNA Purification and 16S rRNA Gene
Amplicon Pyrosequencing
Nucleic acids were extracted with a standard protocol employing
phenol–chloroform and bead-beating (Griﬃths et al., 2000).
DNA quality and quantity was assessed with agarose gel
electrophoresis and spectrophotometry (NanoDrop 1000,
Thermo Scientiﬁc). PCR primers targeting a fragment of
the 16S rRNA gene (V6–V9 region) of most Bacteria were
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used (909F, 5′-ACTCAAAKGAATWGACGG-3′ and 1492R,
5′-NTACCTTGTTACGACT-3′; Berry et al., 2011). The
pyrosequencing primers included the template-speciﬁc sequence,
the sequencing primer and an 8 nt barcode (Hamady et al., 2008).
Amplicon libraries were produced from DNA of both pooled
cecum and colon contents and freshly collected fecal pellets.
A two-step, low cycle number PCR protocol was used to amplify
template DNA to minimize bias associated with barcoded
pyrosequencing primers (Berry et al., 2011). PCR amplicons
from triplicate ampliﬁcations were pooled and puriﬁed using
Agencourt AMPure beads (Beckman Coulter Genomics)
and quantiﬁed with a ﬂuorescent-stain-based kit (Quant-iT
PicoGreen, Invitrogen). Pyrosequencing was performed with
Titanium reagents on a 454 genome sequencer FLX (Roche) as
recommended by the manufacturer. All pyrosequencing data in
the study are archived at NCBI Sequence Read Archive (SRA)
under Accession SRP008057.
Sequencing Data Analysis
Reads were quality-ﬁltered using the amplicon pipeline of
the GS Run Processor (Roche) and the PyroNoise algorithm
in Mothur (Schloss et al., 2011). Sequencing reads were de-
multiplexed using QIIME (Caporaso et al., 2010) and clustered
with UCHIME (Edgar et al., 2011) into operational taxonomic
units (OTUs) at 97% identity (with a minimum length of
250 nt). Taxonomic classiﬁcation was made using the Ribosomal
Database Project (RDP) naïve Bayesian classiﬁer using the
Greengenes database (February 4, 2011 release; Wang et al.,
2007). Alpha and beta diversity metrics, analysis of similarity
(ANOSIM), non-parametric perMANOVA, and redundancy
analysis were calculated using the vegan package (Oksanen
et al., 2013). Indicator species analysis was performed using the
indicspecies package in R (De Cáceres and Legendre, 2009) and
correction for multiple testing was performed with the FDR
method in R. Analysis of variance and Tukey post hoc test were
also performed in R. A tree was constructed from near-full-length
16S rRNA reference gene sequences closely related to sequences
using the maximum likelihood method RAxML (Stamatakis
et al., 2008). Bootstrap analysis was performed (rapid bootstrap
algorithm) using 500 bootstrap iterations. OTU sequences were
then added to the tree using the quick-add parsimony method in
ARB (Ludwig et al., 2004).
Fluorescence In Situ Hybridization
For ﬂuorescence in situ hybridization (FISH) analysis,
oligonucleotide probes speciﬁc for the 16S rRNA or 23S rRNA
of target organisms were hybridized as described previously
(Berry et al., 2012) using formamide concentrations optimized
for each probe for stringent hybridizations (Supplementary Table
S1). Negative control probes (complementary to EUB338 I)
labeled with the dyes FLUOS, Cy3 and Cy5 were also hybridized
to ensure that there was no non-speciﬁc binding of probes to
the samples. Hybridized samples were imaged on a confocal
scanning laser microscope (Zeiss 510 Meta, Oberkochen,
Germany). For each quantiﬁcation, at least 20 ﬁelds of view
(63X) from each sample were analyzed with the image analysis
software daime (Daims et al., 2006).
RESULTS AND DISCUSSION
Repeated DSS-Induced Colitis
Over the course of the experiment mice were treated with DSS to
induce colitis (treatment phase) and then allowed to recover from
DSS treatment (recovery phase) three times. Acute inﬂammation
induced transient loss of body weight after each DSS treatment
(Figure 1A, Repeated measures ANOVA, p = 0.0017), which is
in agreement with previous reports (Berry et al., 2012; Rauch
et al., 2014). The inter-mouse variability in weight loss within the
treatment group was not signiﬁcantly diﬀerent with increasing
cycles of DSS treatment (F test, p > 0.05). The lack of signiﬁcant
diﬀerences in weights of treatment and control mice in the third
cycle are therefore likely due to lower statistical power arising
from reduced numbers of replicates later in the experiment after
sacriﬁce of mice at earlier time points, though may alternatively
reﬂect an adaptation mechanism by the animals in response
to repeated inﬂammation episodes (Figure 1A, Supplementary
Figure S1). Mouse mucosal tissue sampled at the end of each
recovery phase (Figure 1A, time points indicated by large black
circles) indicated remaining pathological damage (Figures 1B,C,
ANOVA, p = 0.001). Importantly, however, no signiﬁcant
diﬀerences in the severity of damage with the number of cycles
of DSS treatment were observed (Figure 1B, ANOVA, p = 0.45),
indicating that the three cycles of DSS treatment did not cause
appreciable increases in sustained disease pathology.
Microbiota Signatures of Prior Colitis
Episodes in Intestinal Flush Samples
The intestinal microbiota is a potential source of non-invasive
biomarkers for monitoring health state (Berry and Reinisch,
2013). We were therefore interested in whether the composition
of the intestinal microbiota is a more sensitive indicator of
inﬂammation history than mucosal tissue pathology during
early recovery phase. We applied a non-parametric multivariate
analysis of variance test (perMANOVA) to determine if
the microbiota composition of intestinal (cecum and colon)
ﬂush samples was associated with previous experimental
treatments. This analysis revealed that prior DSS treatment was
associated with an altered intestinal microbiota composition
(perMANOVA, p < 0.001). This result is consistent with a
previous report that the intestinal microbiota of mice recovering
from DSS treatment has an altered composition (Schwab et al.,
2014). Signiﬁcantly, the number of previous colitis episodes was
also an important factor associated with microbiota composition
(perMANOVA, p = 0.033). These results indicate that despite
similar pathology, intestinal microbiota provided a record of the
history of inﬂammation episodes. Consistent with this result,
clear clustering of samples by treatment was observed with
principal coordinates analysis (PCoA) produced with the Bray–
Curtis dissimilarity metric (Figure 2A). This clustering was
conﬁrmed with the ANOSIM test, which tests the statistical
signiﬁcance of community composition overlap within and
between groups (ANOSIM, R = 0.3379, p = 0.003). This result
is consistent with the observation that repeated disturbances
by ciproﬂoxacin treatment aﬀects the gut microbiota diﬀerently
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FIGURE 1 | Effect of multiple cycles of dextran sodium sulfate (DSS) treatment in mice. (A) Mean change in weight (in percent) for mice given three cycles of
2% DSS in drinking water (indicated by red horizontal bars) as well as untreated control mice (n = 3–11 for each data point). Mice were sampled for intestinal (cecum
and colon) contents and pathology analysis as well as for stool analysis at selected time points (indicated by a circle or triangle, respectively, and the day number).
Error bars indicate 95% confidence interval and asterisks indicate days where for which there is a statistically significant difference in weights between control and
treatment groups (p < 0.05, corrected for multiple comparisons). Weight dynamics for individual mice are shown in Supplementary Figure S1. (B) Pathology scores
of colon mucosal tissue from mice give 0, 1, 2, or 3 cycles of DSS. Pathology scores were calculated as the sum of inflammation severity and extent, crypt depth,
and area of inflammation, as determined by an experienced pathologist. Asterisk indicates statistically significant difference compared with all other groups
(p < 0.05). (C) Representative photomicrographs (10× magnification) of hematoxylin and eosin-stained colon tissues obtained from untreated and DSS-treated
mice. Black scale bars are 200 µm. Arrows indicate infiltrates of immune cells.
between the ﬁrst and second course of antibiotics (Dethlefsen and
Relman, 2011). Additionally, increasing cycles of DSS treatment
led to an increasingly divergent microbiota from control
samples, as determined by redundancy analysis (Figure 2B).
Though some diﬀerences were observed, microbiota richness
and alpha diversity, as quantiﬁed by multiple commonly used
estimators, failed to reveal any consistent trend with respect
to treatment (Figure 2C). Therefore the treatment-associated
alterations in the intestinal microbial community were due
to compositional changes rather than reduction in microbial
richness or dominance of particular organisms.
The intestinal microbiota was dominated by the phyla
Firmicutes and Bacteroidetes, but Tenericutes, Verrucomicrobia,
Proteobacteria, and Deferribacteres were also present at >1%
relative abundance in at least one sample (Supplementary Figure
S2). Prior DSS treatment was associated with signiﬁcant shifts in
themicrobiota composition at the family level but not the phylum
level (perMANOVA, p = 0.012 and p = 0.076, respectively) in
the recovery phase. A dramatic divergent shift was observed
within the phylum Bacteroidetes, in which an increase in
Bacteroidaceae (untreated: 1.8 ± 0.05%, DSS: 5.2 ± 0.7%;
mean ± SEM) was accompanied by a decrease in unclassiﬁed
Bacteroidales (untreated: 34.7 ± 3.7%, DSS: 19.4 ± 2.6%;
mean ± SEM; Figure 2D, ANOVA, p < 0.005 and p < 0.006,
respectively). This pattern has been previously associated with
acute-phase colitis (Berry et al., 2012; Schwab et al., 2014).
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FIGURE 2 | Continued
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FIGURE 2 | Continued
DSS treatment shapes recovery-phase intestinal microbiota
composition and diversity. All data is from intestinal (cecum and colon)
flush samples. (A) Principal coordinates analysis (PCoA) using the Bray–Curtis
dissimilarity metric reveals clustering of samples based on number of DSS
treatment cycles (points are connected by lines to illustrate clustering). This
clustering is statistically supported by the ANOSIM test (R = 0.3379,
p = 0.003). (B) Differences in microbiota composition relative to day 0
untreated samples based on redundancy analysis are shown. All pairwise
comparisons between groups are significant (p < 0.05) except for those
joined by a horizontal bar labeled N.S. (C) Estimation of microbial community
richness (observed OTU richness and Chao1 estimated richness) and diversity
(Shannon and inverse Simpson indices) for each sample. For all analyses
sequence libraries were sub-sampled to 1000 reads. An asterisk indicates a
significant difference between groups (ANOVA and Tukey’s HSD post hoc test,
p < 0.05). (D) Heatmap of the relative abundance of family-level taxa (rows)
for each sample (columns). The abundance is shown in relative percent and
the scale is square root transformed to allow visualization of less abundant
groups. Families with at least 1% relative abundance in at least one sample
are shown. Columns are labeled with sample day and color-coded by DSS
cycle (1 = blue, 2 = red, 3 = orange).
Characteristic inﬂammation-associated microbiota can therefore
also be detected even in recovery-phase mice.
Microbiota Signatures of Prior Colitis
Episodes in Fecal Pellet Samples
In order to monitor longitudinal changes in the microbiota of
individual mice, fecal microbiota samples from mice undergoing
three DSS treatment and recovery cycles were analyzed. Fecal
samples therefore included both acute inﬂammation phase as
well as recovery phase (Figure 1A). Consistent with lumen ﬂush
samples, DSS treatment and treatment cycle were signiﬁcantly
associated with fecal microbiota composition (perMANOVA,
p < 0.001 for both). PCoA revealed a trend of clustering of
fecal pellet microbiota by treatment and DSS cycle (Figure 3A,
ANOSIM, R = 0.3254, p = 0.001). Early-phase recovery samples
from each cycle (days 14 and 20 for cycle 1 and days 33 and 39
for cycle 2) tended to cluster together. DSS treatment destabilized
the fecal microbiota, with community composition varying more
greatly in treated mice compared to untreated mice (Figure 3B,
ANOVA, p < 0.001). This result is in line with observations
that the microbiota is less stable due to colitis, both for acute
as well as relapsing forms such as those characteristic of human
IBDs (Morgan et al., 2012; Angelberger et al., 2013; Berry and
Reinisch, 2013; Schwab et al., 2014). Interestingly, the microbiota
instability caused by multiple episodes of DSS induced-colitis
produced a directional change of the microbial community
away from the starting community over the course of the
experiment, a trend that was not observed in untreated control
samples (Figure 3C and Supplementary Figure S3, ANOVA,
p < 0.001). The microbiota is therefore not entirely resilient
to repeated acute colitis events, at least in the early recovery
phase. This is similar to what has been observed for other
stressors such as treatment with antibiotics (De La Cochetière
et al., 2005; Dethlefsen and Relman, 2011; Fouhy et al., 2012).
This incomplete compositional resilience (Allison and Martiny,
2008) has been suggested to be indicative of a shift of the
microbiota to an alternative stable state, which is deﬁned as
when a community moves from one relatively stable composition
to another stable composition following a disturbance (Shade
et al., 2012). In the present study, microbiota resilience was
further deteriorated after multiple colitis events. The microbiota
may therefore shift into alternative stable states, which include
“dysbiotic states” such as those observed in chronic inﬂammatory
diseases in humans (Frank et al., 2007; Morgan et al., 2012).
Long-term studies are needed to address how stable these states
are over extended periods and if signatures of colitis history are
maintained or lost in the absence of additional colitis events.
Markedly, the richness of the fecal pellet microbiota decreased
with prior DSS treatment and suﬀered additional reductions with
multiple treatments (Figure 3D, ANOVA, p < 0.001 for both
observed OTU richness and Chao1 estimated richness). Though
intestinal ﬂush and fecal samples produced largely similar results,
a signiﬁcant reduction in diversity was not observed in intestinal
ﬂush samples. This is perhaps due to the large contribution of
the cecal microbiota in ﬂush samples, which may not experience
as dramatic diversity-altering changes as the colon microbiota
during colitis. Ecological theory suggests that environments with
intermediate levels of disturbance can support a larger diversity of
organisms (Hall et al., 2012). The loss of diversity observed in the
present study suggests that the disturbances caused by the DSS
stressor are likely far more intense than a diversity-increasing
disturbance might be. Further work is needed to determine if the
loss of compositional resilience and decrease in OTU richness
hold consequences for intestinal microbiota function. It is very
well possible that compositional properties give insight into
functional properties as, for example, loss of gene diversity has
been associated with IBD as well as metabolic disorders and liver
cirrhosis (Le Chatelier et al., 2013; Qin et al., 2010, 2014) and is
predictive for how successful dietary intervention is on reducing
markers of inﬂammation (Cotillard et al., 2013).
The phylum-level composition of the fecal microbiota
was largely similar to the intestinal ﬂush samples, with
a predominance of Bacteroidetes and Firmicutes as well
as Verrucomicrobia, Tenericutes, Proteobacteria, TM7, and
Cyanobacteria (Supplementary Figure S4). The phylum-level
composition was mouse-speciﬁc but was not signiﬁcantly
altered by DSS treatment or treatment cycle (perMANOVA,
p = 0.015, 0.07, and 0.41, respectively). The family-level
composition was also mouse-speciﬁc, but was also signiﬁcantly
altered by DSS treatment and treatment cycle (Figure 3E,
perMANOVA, p = 0.02, 0.001, and 0.005, respectively). This
shift was characterized by a large decrease in the unclassiﬁed
Bacteroidales (untreated: 45.3 ± 2.6%, DSS: 28.5 ± 2.8%;
mean ± SEM) as well as the Clostridiales family XIII
(untreated: 0.4 ± 0.07%, DSS: 0.2 ± 0.02%; mean ± SEM). In
addition, several families increased: Bacteroidaceae (untreated:
1.9 ± 0.3%, DSS: 7.8 ± 1.3%; mean ± SEM), Rikenellaceae
(untreated: 1.1 ± 0.1%, DSS: 2.0 ± 0.3%; mean ± SEM),
Porphyromonadaceae (untreated: 0.6 ± 0.1%, DSS: 1.6 ± 0.3%;
mean ± SEM), and Turicibacteraceae (untreated: 0.1 ± 0.05%,
DSS: 3.3 ± 0.9%; mean ± SEM). Colitis episodes therefore have
a lasting impact on the gut microbiome, and successive episodes
further drive the microbiome into an altered composition even
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FIGURE 3 | Continued
DSS treatment shapes fecal pellet intestinal microbiota composition
and diversity. Fecal pellets were collected immediately upon defecation from
untreated as well as DSS treated (in both acute and recovery phases) mice.
(A) PCoA using the Bray–Curtis dissimilarity metric displays a trend toward
clustering of samples based on number of DSS treatment cycles. This is
statistically supported by the ANOSIM test (R = 0.3254, p = 0.001). Circles
indicate untreated mice, triangles and squares indicate the acute and recovery
phases of inflammation, respectively. (B) Microbiota stability per mouse, as
determined by pairwise Bray–Curtis dissimilarity values calculated from
multiple samples from each mouse. DSS-treated mice (red, #1–5) had
significantly higher dissimilarity values as untreated mice (blue, #6–8),
indicating a less stable microbiota composition throughout the duration of the
entire experiment (Asterisk indicates p < 0.05). (C) The mean and standard
deviation of the microbial community at successive time points relative to day
0 for each mouse based on redundancy analysis. Higher values indicate
increasing divergence from the starting community. An asterisk signifies a
difference between treated and untreated mice at that time point (p < 0.05).
(D) Estimation of microbial community richness (observed OTU richness and
Chao1 estimated richness) and diversity (Shannon and inverse Simpson
indices) for each sample (mean and standard deviation shown). Observed
OTU richness and Chao1 estimated richness were significantly reduced in the
DSS treated group (ANOVA, p < 0.001). For all analyses sequence libraries
were sub-sampled to 1000 reads. (E) Heatmap of the relative abundance of
family-level taxa (rows) for each sample (columns). The abundance is shown in
relative percent and the scale is square root transformed to allow visualization
of less abundant groups. Families with at least 1% relative abundance in at
least one sample are shown.
after recovery from acute inﬂammation. It is not possible to
conclude from the current study, however, whether complete
recovery was achieved between inﬂammation episodes. Further
studies are needed to evaluate whether incomplete or complete
recovery between multiple inﬂammation episodes would have a
diﬀerent impact on the gut microbiota.
Species-Level Operational Taxonomic
Units (OTUs) Associated with Colitis
History
We applied an indicator species analysis to identify which OTUs
were associated with prior colitis episodes. In order to focus on
major members of the gut microbiota only OTUs that had at least
1% relative abundance in one sample were analyzed. In intestinal
ﬂush samples, this analysis identiﬁed seven OTUs increased in
samples from mice with prior DSS-induced colitis (either 1, 2,
or 3 cycles of DSS) and two OTUs associated with untreated
animals (Figure 4A). Indicator OTUs for prior colitis were
aﬃliated with the families Turicibacteraceae, Enterobacteriaceae,
Deferribacteriaceae, and Lachnospiraceae. OTUs associated with
untreated samples were associated with Lachnospiraceae and
unclassiﬁed Bacteroidales. Enterobacteriaceae are often reported
to be associated with inﬂammation and are overrepresented in
individuals with IBD (Morgan et al., 2012; Berry and Reinisch,
2013). Deferribacteriaceae, which are represented by the genus
Mucispirillum, are increased during inﬂammation and have been
suggested to be mucus-dwelling commensals that can cause
disease, so called-pathobionts, because under some conditions
the immune system mounts an IgG response against them
(Robertson et al., 2005; Berry et al., 2012; El Aidy et al.,
2014). Interestingly, though no shifts were observed in the
family Lachnospiraceae as a whole, members of this family have
divergent resilience to colitis events. This mirrors the extensive
diversity of responses to acute colitis by members of this family
(Berry et al., 2012) and suggests the presence of unidentiﬁed
physiological diﬀerences in this group responsible for varying
competitiveness during and in the wake of colitis.
Indicator species analysis of stool samples identiﬁed 19
indicators (eight for three cycles of DSS treatment and
11 for untreated controls, Figure 4B, Supplementary Figure
S5). The majority of indicators from intestinal ﬂush samples
were also identiﬁed as indicators in stool samples (six of
nine). Interestingly, outgrowth of some indicators, such as
Turicibacteraceae OTU 9164, occur to the same extent in each
recovery phase, whereas others such as Enterobacteriaceae OTU
3028 and some OTUs classiﬁed as Lachnospiraceae are increased
to a greater extent in the recovery phase of later DSS cycles. This
may reﬂect a subtle diﬀerence in the ﬁtness of these taxa with
increasing number of inﬂammation episodes, but little is known
about the physiology of members of the Turicibacteraceae and
how they diﬀer from Enterobacteriaceae and Lachnospiraceae.
All three groups likely have an advantage in disturbed gut
environment, either by an altered nutrient environment during
inﬂammation, as has been shown for Escherichia coli (Winter
et al., 2013), or by a loss of colonization resistance after acute
inﬂammation that allows these groups an opportunity to expand
(Stecher et al., 2013). The composition of the mucosa-associated
microbiota is known to generally be distinct from the fecal
microbiota (reviewed in Donaldson et al., 2015) and localized
microbiota at sites of inﬂammation may thus not be identiﬁed in
fecal samples. While fecal samples are not a suitable reﬂection of
the speciﬁc microbiota in various intestinal compartments, they
are still considered to be valuable as an alternative to invasive and
potentially dangerous endoscopic procedures (Vermeire et al.,
2006). The large consistency between indicator OTUs identiﬁed
in the cecum and colon ﬂush samples and the fecal samples
indicates that murine stool microbial communities can indeed
be diagnostic for alterations in the intestinal microbiota and
is therefore a viable source for non-invasive monitoring of
health-associated biomarkers. Diﬀerences between lumen and
stool indicator analysis can be attributed to diﬀerences in the
treatments being tested (one, two, or three cycles of DSS in
the intestinal ﬂush versus three cycles of DSS in the stool),
the inclusion of the cecal microbiota in the intestinal ﬂush
samples, and the greater number of fecal pellet samples. As an
alternative quantitative method to conﬁrm selected sequencing
results, we analyzed the dynamics of several target organisms in
fecal samples using quantitative FISH. FISH analysis conﬁrmed
that in the feces of DSS-treated mice there was increased
Enterobacteriaceae and Akkermansia sp., which have previously
been identiﬁed to be increased in acute-phase colitis (Berry
et al., 2012; Supplementary Figure S6). Akkermansia abundance
peaked in the second cycle at day 39, which was also reﬂected
by an approximately twofold enrichment in the sequencing
data (untreated 6.0 ± 4.2%, DSS: 13.7 ± 6.2%; mean ± SEM).
Additionally, Bacteroides acidifaciens, a colitis-associated species
and an abundant member of the Bacteroidaceae family (Berry
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FIGURE 4 | Bacterial indicators of colitis history. OTUs characteristic for prior DSS treatment were determined using indicator species analysis. Heatmaps of
the relative abundance of each OTU is shown. Only abundant OTUs (>1% relative abundance in at least one sample) were evaluated. (A) Indicator OTUs from gut
flush samples. (B) Indicator OTUs from stool samples. Indicators from stool were identified by comparing samples from untreated mice with samples from mice
treated with three cycles of DSS (day 52) using indicator species analysis. Only OTUs that were significantly associated with prior treatment or controls are shown
(p < 0.05). OTUs identified in both intestinal flush and stool samples are shown in bold. Asterisks after the OTU ID indicates that this OTU was also identified in
intestinal flush (cecum and colon) samples as an indicator of acute DSS-induced colitis or of untreated mice in a previous study (all OTUs share 100% sequence
similarity over at least 400 nt with previously identified OTUs; Berry et al., 2012). See Supplementary Figure S5 for a phylogenetic tree of indicator OTUs.
et al., 2012), also exhibited elevated levels during inﬂammation
but then decreased rapidly post-colitis and was therefore not
identiﬁed as an indicator of inﬂammation history. The DSS-naïve
(health) indicator Lachnospiraceae OTU 207, which was also
identiﬁed as an indicator in a previous study (called OTU 11021
in the previous study; Berry et al., 2012), was present in one DSS-
naïve mouse at very high abundance and recovered after the ﬁrst
treatment, but was lost and did not recover again after subsequent
treatments. The loss of this Lachnospiraceae OTU is an example
of the individualized response and the eroded resilience of the
murine gut microbiota after multiple DSS-induced disturbances.
CONCLUSION
In the present study, using intestinal ﬂush and stool samplings,
we have characterized the response of the intestinal microbiota
to repeated acute colitis episodes. Importantly, signatures in
the microbiota reﬂected the history of colitis. The microbiota
therefore represents a sensitive read-out for acute and historical
health state. Using longitudinal fecal sampling of animals, we
found that the microbiota of mice with a history of colitis was
destabilized and exhibited a directional trajectory increasingly
diverging away from the microbiota prior to treatment. OTUs
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associated with prior colitis episodes were identiﬁed both in
intestinal ﬂush and stool samples, and were largely consistent.
Reduced community resilience may have implications for
microbiome function as well as susceptibility to additional colitis
events. Possible biomarkers in the human microbiota will very
likely be diﬀerent from those in mice, and therefore future work
will be needed to establish the relevance in the context of human
disease and to identify biomarkers in the human microbiota.
However, our results indicate that the use of stool samples to
monitor bacterial biomarkers of inﬂammation state in individuals
with chronic and relapsing IBDs is a promising approach.
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